Evidence map›Paper›PMID 41210143›Full record

ArticleFrontiers in psychiatry2025

Effectiveness of magnetic seizure therapy versus electroconvulsive therapy for major depressive episode in China: protocol for a double-blind, randomized, non-inferiority trial.

TianHong Zhang, YongGuang He, Sha Liu, MingLiang Ju, YiYi Yang, RunChun Zhou, YaWen Hong, YanYan Wei, XiaoChen Tang, HaoYang Zheng and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06409325 (Effectiveness of Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Major Depressive Episode), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06409325 narecruitingnot on this map

Effectiveness of Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Major Depressive Episode

TypeinterventionalSponsorShanghai Mental Health CenterRan2024 to 2026Enrolled210ConditionsMajor Depressive Disorder (MDD)ArmsMST, ECT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

TianHong Zhang *Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
YongGuang He *Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
Sha Liu *Department of Psychiatry, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China.
MingLiang JuShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
YiYi YangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
RunChun ZhouShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
YaWen HongShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
YanYan WeiShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
XiaoChen TangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
HaoYang ZhengShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
YuPing JiaShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
HaiChun LiuDepartment of Automation, Shanghai Jiao Tong University, Shanghai, China.
DongSheng ZhouDepartment of Psychiatry, Ningbo Kangning Hospital, Ningbo, China.
Qiang HuDepartment of Psychiatry, Wuhu Hospital of Anding Hospital (The Fourth People's Hospital of Wuhu), Anhui, China.
Ran WangDepartment of Psychiatry, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei,, China.
Wei ZhengThe Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
LingYun ZengDepartment of Psychiatric Rehabilitation, Shenzhen Kangning Hospital, Shenzhen, China.
CuiXia AnDepartment of Psychiatry, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei,, China.
ChunBo LiShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
JiJun WangShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Neuromodulation Center, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electroconvulsive therapy (ECT) has been a cornerstone in treating Major Depressive Disorder (MDD), demonstrating high efficacy but often limited by cognitive side effects. As an alternative, magnetic seizure therapy (MST) has emerged, offering comparable antidepressant effects with potentially fewer cognitive adverse outcomes. This study aimed to compare the efficacy, safety, and cognitive impact of MST and ECT. This multicenter, double-blind, parallel, non-inferiority randomized clinical trial will be conducted at seven clinical centers. Participants diagnosed with MDD will be randomly allocated to either the ECT or MST group. Each center aims to recruit 30 participants, resulting in a total sample size of 210. The intervention includes 12 sessions over 4 weeks, followed by 12-week follow-up. Assessments (the 24-item Hamilton Depression Rating Scale (HDRS-24), Hamilton Anxiety Scale (HAMA), 8 cognitive tests, Electroencephalography, electrocardiography) occur at baseline, post-sessions 3/6/9/12 (3 hours after each session), and 4-/8-/12-week follow-ups. The primary outcome is the change in HDRS-24 total score from baseline to the 12-week follow-up, which is assessed after the completion of the 12-session acute treatment phase (conducted over 4 weeks) and a subsequent 12-week post-treatment observation period. Randomization and blinding protocols will be strictly followed to ensure unbiased treatment administration and assessment. This trial aims to provide robust evidence that MST is as effective as ECT in reducing depressive symptoms (assessed via HDRS-24) and to confirm its superior cognitive safety, with the Hopkins Verbal Learning Test-Revised as an additional primary outcome to evaluate verbal memory changes. Remaining cognitive measures will serve as secondary outcomes. Exploratory analyses will examine electroencephalography and electrocardiography data to identify potential neurophysiological biomarkers. If successful, this trial could significantly influence clinical practices and improve seizure treatment for patients with MDD. Clinical trial registration: ClinicalTrials.gov, identifier NCT06409325.

Indexed as

electroconvulsive therapymagnetic seizure therapymajor depressive disorderrandomized controlled trialseizure treatment

Identifiers

PMID41210143
PMCPMC12589047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.